Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2530
-0.0060 (-2.32%)
Oct 28, 2025, 3:59 PM EDT

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021FY 2020FY 20192014 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2014 - 2018
Innovative Immunotherapies for Cancer
1.93M
Log In
Log In
Log In
Log In
Upgrade
Innovative Immunotherapies for Cancer Growth
14.80%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021FY 2020FY 20192014 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2014 - 2018
United States, Germany, United Kingdom and Netherlands
1.93M
Log In
Log In
Log In
Log In
Upgrade
United States, Germany, United Kingdom and Netherlands Growth
14.80%
Log In
Log In
Log In
Log In
Upgrade